Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Jan 2023: Trial registered, NCT05702905
  2. 9 May 2023: Trial started, NCT05702905

The trials

NCT05702905: Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

State
State not given
Phase
Phase 4
People
75 planned
Started
9 May 2023
Primary completion
31 Dec 2024
Arms
semaglutide and metformin
Results
None posted
Papers
doi:10.1007/bf03401383, doi:10.1007/s00404-022-06700-3, doi:10.1007/s40618-021-01666-6, doi:10.1016/j.rbmo.2019.04.017, doi:10.1097/cm9.0000000000001712, doi:10.1111/cen.13454, doi:10.1210/clinem/dgaa285, doi:10.1530/eje-13-0797, doi:10.1530/eje-18-0175, doi:10.17219/acem/151695, doi:10.3389/fendo.2022.945609
  1. 27 Jan 2023: Trial registered
  2. 9 May 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.